Peyton Manning and Eli Manning are arguably the most famous sibling duo in NFL history. Both of them went on to have stellar careers in the league in their own right, with the star QBs each winning two Super

Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has now introduced a pill version of its GLP-1 weight loss drug. Eli Lilly's valuation looks stretched at this point -- both against the industry and overall market.

Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in 2022 and 2023, respectively. Like Novo, it saw sales soar as doctors initially prescribed its diabetes drug off-label for weight loss too.

Back in 2019, the New York Giants were already drifting. After back-to-back losing years, the front office went hunting for help to protect the Eli Manning era.

Peyton Manning has cemented his legacy as one of the best NFL quarterbacks of all time, getting inducted into the Pro Football Hall of Fame in 2021 after winning two Super Bowls during an 18-season career. However, back in 1998, the future was more of a question mark.

Conveniently, Peyton Manning and Ben Roethlisberger avoided playing Eli Manning in the Super Bwl, which he didn't let go unnoticed. Eli Manning is best known for beating Tom Brady in the Super Bowl (twice), but he never got to play his brother, Peyton Manning, or Pittsburgh Steelers legend Ben Roethlisberger in the big game.

Novo Nordisk ( NVO +1.68%) was once the top player in the weight loss drug market. The company's medicine, Wegovy, practically became a household name. However, it has lost the top spot to its eternal rival, Eli Lilly ( LLY +1.64%).

Wall St. provides estimates for future stock prices of Eli Lilly from 2026 to 2030 based on projected revenue and net income.

Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its earnings to rise in double-digits.